Entering text into the input field will update the search result below

TapImmune enrolls first patient in Phase 2 clinical trial for treating triple-negative breast cancer

  • TapImmune (TPIV) announces that the first patient has been enrolled in a Phase 2 clinical trial of TapImmune's therapeutic vaccine candidate TPIV200.
  • The 280-patient trial, received $13.3M in grant funding from the U.S. Department of Defense to evaluate the prevention of cancer recurrence in women with triple-negative breast cancer who have completed first-line surgery and radiotherapy/chemotherapy.
  • TPIV200 is a peptide-based cancer vaccine that has been shown to induce a robust and long-lasting "memory" T-cell immune response directed against folate receptor alpha.

Recommended For You

More Trending News

About MRKR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRKR--
Marker Therapeutics, Inc.